Prostate cancer survival estimates: An application with piecewise hazard function derivation

Determining of survival & hazard in patients with pemphigus in Kerman

  the incidence of survival  analysis and hazard rates in 55 patients with pemphingus have been determined for a period of 12 years from 1989-2000.the effect of pemphigus type,sex,age and the method of treatment were evaluated seperately.for this the  equation ht(x)=ho(t) exp{bi xi}was chosen in which hois the baseline hazard in ziro time,ht is hazard happened later(in timet)b is regression co...

Structural Multivariate Function Estimation: Some Automatic Density and Hazard Estimates

Abstract: Structures such as independence of random variables in probability densities and hazard proportionality in covariate dependent hazard functions have important interpretations in statistical analysis. Such structures can be characterized by term eliminations from an analysis of variance (ANOVA) decomposition in log density or log hazard. Nonparametric estimation of these functions with...

Abiraterone Boosts Prostate Cancer Survival

Final results of a phase III trial confirm that treatment with abiraterone prolongs overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) that has progressed after docetaxel therapy. Over a median 20 month follow-up, median OS was 15.8 months for abiraterone (Zytiga®) plus prednisone compared with 11.2 months for placebo plus the steroid (P<0.0001), Karim Fizazi, MD, ...

Conditional survival estimates for cancer patients

Prognostic factors influencing prostate cancer-specific survival in non-castrate patients with metastatic prostate cancer.

BACKGROUND In non-castrate prostate cancer (PCa), the prognostic value of the number of metastases on prostate cancer-specific survival (PCSS) is not well studied. METHODS We retrospectively analyzed the medical records of 1,206 patients, referred for radiotherapy of the prostate (bed) following diagnosis of PCa. Distant metastases (nodal, skeletal, and/or visceral) developed in 121 patients ...